ADMA BIOLOGICS, INC. (ADMA) Net margin 2016–2025
ADMA BIOLOGICS, INC. (ADMA) net profit margin by fiscal year — reported net income divided by reported revenue.
28.8%FY2025 · since FY2016: -183.1% → 28.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 28.8% | -17.6 pp |
| FY2024 | 46.4% | +57.3 pp |
| FY2023 | -10.9% | +31.8 pp |
| FY2022 | -42.8% | +45.7 pp |
| FY2021 | -88.5% | +90.9 pp |
| FY2020 | -179.4% | -14.9 pp |
| FY2019 | -164.5% | +222.6 pp |
| FY2018 | -387.1% | -194.8 pp |
| FY2017 | -192.3% | -9.2 pp |
| FY2016 | -183.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ADMA financial trends
ADMA RevenueADMA Net incomeADMA Gross profitADMA Gross marginADMA Operating incomeADMA Operating marginADMA Operating cash flowADMA Free cash flowADMA Capital expendituresADMA Return on equityADMA Stock buybacksADMA Dividends paidADMA Total assetsADMA Total liabilitiesADMA Shareholders’ equityADMA overview →